Medarex to Receive Milestone Payment from FibroGen
15-Jul-2009
- USA
FG-3019 is a fully human monoclonal antibody generated using Medarex's UltiMAb(R) technology against connective tissue growth factor (CTGF). Under the agreement with FibroGen, Medarex could receive future milestone payments and sales-based royalty payments.
Organizations
FibroGen
Medarex
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.